SARS-CoV2 CR3-C2 human neutralizing mAb

The ongoing global health challenge posed by SARS-CoV-2 underscores the critical need for effective therapeutic interventions, and neutralizing antibodies have emerged as a highly promising strategy for both treatment and prevention of COVID-19. These antibodies specifically bind to the viral spike protein, primarily targeting the receptor-binding domain (RBD), and thereby block the virus from entering human cells via the ACE2 receptor. Humanized neutralizing antibodies, such as Abwiz Bio’s CR3C2 (SKU#2830), are particularly significant for therapeutic applications due to their reduced immunogenicity in human patients, minimizing the risk of adverse immune responses often associated with non-human antibodies. The development of such antibodies has been vital in providing immediate passive immunity and can serve as a crucial tool for vulnerable populations or those who cannot mount a sufficient immune response to vaccines.
Abwiz Bio’s commitment to developing high-quality humanized antibodies is exemplified by our proprietary STage Enhanced Maturation (STEM™) technology. This innovative platform allows for the simultaneous humanization and affinity maturation of antibodies, effectively mimicking the natural immune system to engineer antibodies with enhanced function, including improved affinity and specificity. For CR3C2, this means an antibody optimized not only for broad and potent neutralization of SARS-CoV-2, including emerging variants, but also for optimal developability as a therapeutic. By integrating advanced computational design with comprehensive benchtop selection, our STEM™ approach ensures that CR3C2, a human IgG1k antibody, offers a robust and reliable solution for combating SARS-CoV-2 infection, representing a significant advancement in antibody-based therapeutics